A Phase 4 interventional study of sildenafil in Sexual Dysfunction and Depression, sponsored by University of New Mexico. Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2006-09-12.
Sponsored by University of New Mexico · Phase 4, Interventional, and Treatment
This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD.
This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD. Women (n=100) with MDD-remission and SRI-AASD were randomized to receive sildenafil (50-100mg) or placebo for 8 weeks, followed by 8-weeks open-label extension. Sexual function was assessed using the Clinical Global Impression-Sexual Function (CGI-SF), with positive response defined as a score \<3, and UNM-SFI, ASEX, SFQ-FSD sexual function questionnaires. Depression was monitored using the HAM-D17. Hypothalamic-pituitary-adrenal-gonadal hormones were measured at baseline and DB-endpoint.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 100 is above the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →University of New Mexico is the lead sponsor of 306 studies on the registry; 28 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 23 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:S Subjects will be females only, ages 18 to 50 years.
Subjects must meet at least one of the following criteria:
Clinically significant orgasm delay with masturbation or intercourse that according to patient opinion:
Exclusion Criteria:
Clinical global improvement in sexual function
UNM-Sexual function inventory
Arizona Sexual Function Scale
Female sexual function questionnaire
This study is completed, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of New Mexico